These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 8203858

  • 1. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.
    Mukherjee J, Zuckier LS, Scharff MD, Casadevall A.
    Antimicrob Agents Chemother; 1994 Mar; 38(3):580-7. PubMed ID: 8203858
    [Abstract] [Full Text] [Related]

  • 2. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.
    Mukherjee J, Feldmesser M, Scharff MD, Casadevall A.
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1398-405. PubMed ID: 7492075
    [Abstract] [Full Text] [Related]

  • 3. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.
    Mukherjee S, Lee S, Mukherjee J, Scharff MD, Casadevall A.
    Infect Immun; 1994 Mar; 62(3):1079-88. PubMed ID: 8112842
    [Abstract] [Full Text] [Related]

  • 4. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
    Mukherjee J, Kozel TR, Casadevall A.
    J Immunol; 1998 Oct 01; 161(7):3557-68. PubMed ID: 9759877
    [Abstract] [Full Text] [Related]

  • 5. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages.
    Mukherjee S, Lee SC, Casadevall A.
    Infect Immun; 1995 Feb 01; 63(2):573-9. PubMed ID: 7822024
    [Abstract] [Full Text] [Related]

  • 6. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection.
    Feldmesser M, Casadevall A.
    J Immunol; 1997 Jan 15; 158(2):790-9. PubMed ID: 8992996
    [Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.
    Cleare W, Cherniak R, Casadevall A.
    Infect Immun; 1999 Jun 15; 67(6):3096-107. PubMed ID: 10338526
    [Abstract] [Full Text] [Related]

  • 8. J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins.
    Mukherjee S, Feldmesser M, Casadevall A.
    J Infect Dis; 1996 May 15; 173(5):1222-31. PubMed ID: 8627076
    [Abstract] [Full Text] [Related]

  • 9. Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro.
    Feldmesser M, Mukherjee J, Casadevall A.
    J Antimicrob Chemother; 1996 Mar 15; 37(3):617-22. PubMed ID: 9182119
    [Abstract] [Full Text] [Related]

  • 10. Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.
    Mukherjee J, Scharff MD, Casadevall A.
    Infect Immun; 1995 Sep 15; 63(9):3353-9. PubMed ID: 7642262
    [Abstract] [Full Text] [Related]

  • 11. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.
    Nussbaum G, Anandasabapathy S, Mukherjee J, Fan M, Casadevall A, Scharff MD.
    Infect Immun; 1999 Sep 15; 67(9):4469-76. PubMed ID: 10456888
    [Abstract] [Full Text] [Related]

  • 12. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
    Maitta RW, Datta K, Chang Q, Luo RX, Witover B, Subramaniam K, Pirofski LA.
    Infect Immun; 2004 Aug 15; 72(8):4810-8. PubMed ID: 15271943
    [Abstract] [Full Text] [Related]

  • 13. Antibody interactions with the capsule of Cryptococcus neoformans.
    Feldmesser M, Rivera J, Kress Y, Kozel TR, Casadevall A.
    Infect Immun; 2000 Jun 15; 68(6):3642-50. PubMed ID: 10816523
    [Abstract] [Full Text] [Related]

  • 14. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan.
    Casadevall A, DeShaw M, Fan M, Dromer F, Kozel TR, Pirofski LA.
    Infect Immun; 1994 Sep 15; 62(9):3864-72. PubMed ID: 8063403
    [Abstract] [Full Text] [Related]

  • 15. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans].
    Rodríguez Sánchez H, Pupo Antúnez M, Ilnait MT, Otero A, Martínez Machín G.
    Rev Cubana Med Trop; 2005 Sep 15; 57(2):162-4. PubMed ID: 17966590
    [Abstract] [Full Text] [Related]

  • 16. Cryptococcus neoformans infection can elicit protective antibodies in mice.
    Mukherjee J, Scharff MD, Casadevall A.
    Can J Microbiol; 1994 Oct 15; 40(10):888-92. PubMed ID: 8000967
    [Abstract] [Full Text] [Related]

  • 17. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
    Casadevall A, Mukherjee J, Devi SJ, Schneerson R, Robbins JB, Scharff MD.
    J Infect Dis; 1992 Jun 15; 165(6):1086-93. PubMed ID: 1583327
    [Abstract] [Full Text] [Related]

  • 18. Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans.
    Feldmesser M, Kress Y, Casadevall A.
    J Infect Dis; 1998 Jun 15; 177(6):1639-46. PubMed ID: 9607844
    [Abstract] [Full Text] [Related]

  • 19. Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments.
    Taborda CP, Casadevall A.
    J Immunol; 2001 Feb 01; 166(3):2100-7. PubMed ID: 11160261
    [Abstract] [Full Text] [Related]

  • 20. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action.
    Dromer F, Charreire J.
    J Infect Dis; 1991 May 01; 163(5):1114-20. PubMed ID: 2019759
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.